Skip to Main Content

Andrew S. Feigin, MD

Adjunct Professor, Department of Neurology

Positions

Adjunct Professor, Department of Neurology at NYU Grossman School of Medicine

Associate Chair, NYU Network and Clinical Research, Department of Neurology

Co- Executive Director, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorder

Graduate Education

MD from Columbia University

Is this your profile?
Edit profile

These focus areas and their associated publications are derived from medical subject headings from PubMed.
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Reilmann, Ralf; Anderson, Karen E; Feigin, Andrew; Tabrizi, Sarah J; Leavitt, Blair R; Stout, Julie C; Piccini, Paola; Schubert, Robin; Loupe, Pippa; Wickenberg, Anna; Borowsky, Beth; Rynkowski, Gail; Volkinshtein, Rita; Li, Thomas; Savola, Juha-Matti; Hayden, Michael; Gordon, Mark Forrest; ,

Lancet. Neurology. 2024 Mar; 23(3):243-255

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Feigin, Andrew; Evans, Elizabeth E; Fisher, Terrence L; Leonard, John E; Smith, Ernest S; Reader, Alisha; Mishra, Vikas; Manber, Richard; Walters, Kimberly A; Kowarski, Lisa; Oakes, David; Siemers, Eric; Kieburtz, Karl D; Zauderer, Maurice

Nature medicine. 2024 Feb; 30(2):606

Art therapy as a comprehensive complementary treatment for Parkinson's disease

Ettinger, Tom; Berberian, Marygrace; Acosta, Ikuko; Cucca, Alberto; Feigin, Andrew; Genovese, Danilo; Pollen, Travis; Rieders, Julianne; Kilachand, Rohita; Gomez, Clara; Kaimal, Girija; Biagioni, Milton; Di Rocco, Alessandro; Ghilardi, Felice M; Rizzo, John-Ross

Frontiers in human neuroscience. 2023; 17:1110531

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Feigin, Andrew; Evans, Elizabeth E; Fisher, Terrence L; Leonard, John E; Smith, Ernest S; Reader, Alisha; Mishra, Vikas; Manber, Richard; Walters, Kimberly A; Kowarski, Lisa; Oakes, David; Siemers, Eric; Kieburtz, Karl D; Zauderer, Maurice

Nature medicine. 2022 Oct; 28(10):2183-2193

Emerging therapeutics in Huntington's disease

Wiggins, Robert; Feigin, Andrew

Expert opinion on emerging drugs. 2021 09; 26(3):295-302

Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia

Fujita, Koji; Peng, Shichun; Ma, Yilong; Tang, Chris C; Hellman, Matthew; Feigin, Andrew; Eidelberg, David; Dhawan, Vijay

Journal of neurology. 2021 Jun; 268(6):2246-2255

Art therapy for Parkinson's disease

Cucca, Alberto; Di Rocco, Alessandro; Acosta, Ikuko; Beheshti, Mahya; Berberian, Marygrace; Bertisch, Hilary C; Droby, Amgad; Ettinger, Tom; Hudson, Todd E; Inglese, Matilde; Jung, Yoon J; Mania, Daniella F; Quartarone, Angelo; Rizzo, John-Ross; Sharma, Kush; Feigin, Andrew; Biagioni, Milton C; Ghilardi, M Felice

Parkinsonism & related disorders. 2021 Mar; 84:148-154

Huntington's Disease: New Frontiers in Therapeutics

Pan, Ling; Feigin, Andrew

Current neurology & neuroscience reports. 2021 Feb 14; 21(3):10

See All Publications (113)

Read Story